Shares of Smith & Nephew surged to £1,190 on November 5, their best single-day move in months, after the medical-device maker reported accelerating quarterly revenue growth — even as management quietly lowered the bar for the full year. The tension between improving execution and shrinking ambitions defines the investment debate heading into 2027. Smith & Nephew Jumps 7.7% on Faster Growth and Deal Intrigue — but Is the Market Ignoring a Shrinking Orthopaedics Problem?
Shares of Smith & Nephew rocketed 7.7% to £1,190 on November 5, a striking rally for a company that simultaneously slashed its profit forecast. Investors appear to be rewarding two things: accelerating quarterly momentum and a tantalizing hint that the company's weakest division might be sold or restructured. The question is whether optimism is outrunning reality.
Sports Medicine Is Carrying the Company — and It Needs To
Q3 underlying revenue growth hit 3.4%, an acceleration from Q2, powered by Sports Medicine & ENT, which posted double-digit growth in joint repair for the fourth consecutive quarter.
Sports Medicine & ENT led all units at 7.9% underlying growth. That matters because management is explicitly prioritizing investment behind Sports Medicine and Advanced Wound Management, where it sees "a clear path to market leadership." If those divisions sustain high-single-digit growth, they can offset trouble elsewhere — but they must.
US Hips and Knees Are in Serious Trouble
US knee implant revenue fell 7.3% and US hips declined 1.0% , dragging the broader Orthopaedics unit to just 2.5% growth. Orthopaedics accounts for roughly 40% of annual sales , so weakness here carries outsized weight. Stryker recently cut guidance too, citing similar joint-sales weakness , suggesting an industry-wide headwind rather than purely a Smith & Nephew execution gap — cold comfort for shareholders.
The J&J Deal Collapsed, but Strategic Optionality Lives On
Smith & Nephew confirmed it approached Johnson & Johnson earlier this year about combining their orthopaedics businesses, but those conversations have ended.
Reports indicate talks stalled over leadership disagreements. Still, the board said it will "continue to actively explore the full range of strategic options." J.P. Morgan noted that bulls will welcome the confirmation of an active strategic review, while bears may question the timeline and who would actually buy the orthopaedics arm.
The Numbers Behind the Guidance Cut Are Substantial
Full-year revenue growth guidance fell to ~3% from ~4%, trading profit expectations dropped to ~$1.25 billion from ~$1.3 billion, and free cash flow guidance was trimmed to ~$750 million from ~$800 million.
The company maintained its target of ~95% cash conversion , signaling the balance sheet remains healthy. Meanwhile, a $500 million share buyback is half-complete , supporting the stock. The rally suggests the market is pricing in a strategic shake-up — but if no deal materializes, the underlying deceleration in orthopaedics will be hard to ignore.